HNRNPA3P6: A Potential Drug Target and Biomarker (G653115)

Target Name: HNRNPA3P6

NCBI ID: G653115

HNRNPA3P6

Other Name(s): heterogeneous nuclear ribonucleoprotein A3 pseudogene 6 | Heterogeneous nuclear ribonucleoprotein A3 pseudogene 6

HNRNPA3P6: A Potential Drug Target and Biomarker

Heterogeneous nuclear ribonucleoprotein (HNRNPA3) is a protein that plays a crucial role in the regulation of gene expression and cell signaling. Mutations in the HNRNPA3 gene have been linked to a range of cellular and computational processes, including altered gene expression, RNA binding, and protein stability. HNRNPA3P6, a specific pseudogene of the HNRNPA3 gene, has been identified as a potential drug target and biomarker.

The HNRNPA3 gene is located on chromosome 19p and encodes a protein that is composed of multiple domains, including a hypervariable region (HVR), a transmembrane region (TM), a cytoplasmic domain (CPD), and a nuclear domain (ND). The HVR is the region of the protein that is involved in RNA binding and has been implicated in the regulation of gene expression. The TM and CPD domains are involved in the protein's stability and localization to the cell membrane, while the ND domain is responsible for the protein's nuclear localization and stability.

HNRNPA3P6 is a specific pseudogene that is located in the HVR region of the HNRNPA3 gene. It is characterized by a unique nucleotide sequence that is different from the other pseudogenes of the HNRNPA3 gene. The HNRNPA3P6 protein has also been shown to have unique functional properties compared to the other pseudogenes. For example, HNRNPA3P6 has a more compact structure than other pseudogenes, with a shorter C-terminus and a longer N-terminus. This may indicate that the protein has a different stability or function in the cell.

HNRNPA3P6 has been shown to play a role in regulating gene expression in various cell types. For example, studies have shown that HNRNPA3P6 can interact with the transcription factor, p53, and can modulate the expression of target genes. Additionally, the protein has been shown to play a role in the regulation of cell signaling pathways, including the TGF-β pathway.

HNRNPA3P6 has also been shown to be involved in the regulation of cellular processes that are important for the development and progression of cancer. For example, studies have shown that HNRNPA3P6 can be expressed in various cancer cell types and that it plays a role in the regulation of cell proliferation and survival. Additionally, the protein has been shown to be involved in the regulation of angiogenesis, the process by which new blood vessels are formed in cancer.

Due to its unique structure and function, HNRNPA3P6 has potential as a drug target or biomarker. Studies have shown that inhibiting the activity of HNRNPA3P6 can lead to a variety of cellular and biological effects, including the inhibition of cell proliferation, the regulation of gene expression, and the inhibition of cellular processes that are important for the development and progression of cancer.

In conclusion, HNRNPA3P6 is a protein that has unique functional properties and has been shown to play a role in the regulation of gene expression and cellular processes. The protein has potential as a drug target or biomarker for a variety of diseases, including cancer. Further research is needed to fully understand the protein's role in these processes and to develop effective therapies based on its unique properties.

Protein Name: Heterogeneous Nuclear Ribonucleoprotein A3 Pseudogene 6

The "HNRNPA3P6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HNRNPA3P6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets